Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

colorectal cancer, molecular residual disease, stage ii, stage iii, circulating tumor deoxyribose nucleic acid (ctdna) positive, signatera test, recurrence prevention, early stage resectable colorectal cancer (crc), curative-intent therapy, microsatellite-stable (mss), microsatellite instability (msi) - low, mismatch repair proficient (pmmr)